



Taiho Oncology To Present Data on Futibatinib (TAS-120) at the AACR Annual Meeting 2020

PRINCETON, N.J., June 4, 2020 – Taiho Oncology, Inc. today announced that preclinical data for futibatinib (TAS-120) will be presented online during the American Association for Cancer Research (AACR) Virtual Annual Meeting II 2020 from June 22-24. Key presentations include:

- Futibatinib (TAS-120) plus chemotherapy demonstrated a synergistic effect across various *FGFR*-deregulated cancer cell lines and xenograft models (Abstract 564). Results will be shared online as a poster presentation on June 22, 2020. The abstract for this presentation is available on the AACR website: <https://www.abstractsonline.com/pp8/#!/9045/presentation/2469>
- Synergistic antitumor activity of futibatinib (TAS-120), a *FGFR*1-4 inhibitor, and PI3K pathway inhibitors (Abstract 659). Results will be shared online as a poster presentation on June 22, 2020. The abstract for this presentation is available on the AACR website: <https://www.abstractsonline.com/pp8/#!/9045/presentation/1864>
- Synergistic antitumor activity of futibatinib, an *FGFR*1-4 inhibitor, and TAS-117, a selective AKT inhibitor, in *FGFR*-deregulated cancer models (Abstract 661). Results will be shared online as a poster presentation on June 22, 2020. The abstract for this presentation is available on the AACR website: <https://www.abstractsonline.com/pp8/#!/9045/presentation/1873>

“We are pleased to present these pre-clinical data for futibatinib, in combination with chemotherapy or targeted agents,” said Martin J. Birkhofer, MD, Senior Vice President and Chief Medical Officer, Taiho Oncology, Inc. “These data advance our research of novel combination regimens as potential options to be tested in clinical trials.”

In May 2018, the U.S. Food and Drug Administration Office of Orphan Drug Development granted futibatinib orphan drug status for the treatment of cholangiocarcinoma.

About Futibatinib (TAS-120)

Futibatinib (TAS-120) is an investigational, oral, potent, selective, and irreversible small-molecule inhibitor of *FGFR*1, 2, 3, and 4 being studied as a potential treatment for patients with advanced solid tumors, with *FGFR*1-4 genetic aberrations, including cholangiocarcinoma, who were previously treated with chemotherapy or other therapies. Futibatinib selectively and irreversibly binds to the ATP binding pocket of *FGFR*1-4 resulting in the inhibition of *FGFR*-mediated signal transduction pathways, reduced tumor cell proliferation and increased tumor cell death in tumors with *FGFR*1-4 genetic aberrations.

About Taiho Oncology, Inc. (U.S.)

Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has established a world class clinical development organization that works urgently to develop innovative cancer treatments and has built a commercial business in the U.S. Taiho has an oral oncology pipeline consisting of both novel antimetabolic agents and selectively targeted agents. Advanced technology, dedicated researchers, and state of the art facilities are helping us to define the way the world treats cancer. It's our work; it's our passion; it's our legacy.

For more information about Taiho Oncology, please visit:

<https://www.taihooncology.com/us/>

For more information about Taiho Pharmaceutical Co., Ltd., please visit:

<https://www.taiho.co.jp/en/>

For more information about Otsuka Holdings Co., Ltd., please visit:

<https://www.otsuka.com/en/>

###

U.S. Media Contact:

Craig Heit

GCI Health on behalf of Taiho Oncology

Taihooncology@gcihealth.com

212-798-9919

PL-PM-US-0021 06/20